Redskins’ Jordan Reed: Absence related to stem-cell treatment – CBSSports.com

Reed's current absence is the result of an unexpected side effect of a stem-cell treatment on a lingering big toe sprain, Michael Phillips of the Richmond Times-Dispatch reports. "That kind of flared it up a bit on me," Reed said. "Now I'm just letting it calm down before I get out there."

Despite his lengthy injury history, Reed's placement on the PUP list was among the most surprising decisions when training camps kicked off. He has since clarified that his toe injury plagued him all off last season, when he missed four games due to a concussion and shoulder injury, and into the offseason. Given a recommendation to rest before restarting on-field activity, Reed doesn't have a particular timetable for a return. Because Vernon Davis (hamstring) has also been sidelined during the early stages of camp, Niles Paul, Jeremy Sprinkle and Derek Carrier have certainly earned valuable snaps with the first- and second-team offenses.

More:
Redskins' Jordan Reed: Absence related to stem-cell treatment - CBSSports.com

Gene editing used to repair diseased genes in embryos – NHS Choices

Thursday August 3 2017

The technique means individual genes can be edited

"Deadly gene mutations removed from human embryos in landmark study," reports The Guardian. Researchers have used a gene-editing technique to repair faults in DNA that can cause the often-fatal heart condition, hypertrophic cardiomyopathy.

This inherited heart condition is caused by a genetic change (mutation) in one or more genes. Babies born with hypertrophic cardiomyopathy have diseased and stiff heart muscles, which can lead to sudden unexpected death in childhood and in young athletes; often because they don't realise they have the condition and so put their heart under strain when exercising.

In this latest study researchers used a technique called CRISPR-cas9 to target and then remove faulty genes. CRISPR-cas9 acts like a pair of molecular scissors, allowing scientists to cut out certain sections of DNA. The technique has attracted a great deal of excitement in the scientific community since it was released in 2014. But as yet, there have been no practical applications for human health.

The research is at an early stage and cannot legally be used as treatment to help families affected by hypertrophic cardiomyopathy. And none of the modified embryos were implanted in the womb.

While the technique showed a high degree of accuracy, it's unclear whether it is safe enough to be developed as a treatment. The sperm used in the study came from just one man with faulty genes, so the study needs to be repeated using cells from other people, to be sure the findings can be replicated.

Scientists say it is now important for society to start a discussion about the ethical and legal implications of the technology. It is currently against the law to implant genetically altered human embryos to create a pregnancy, although such embryos can be developed for research.

The study was carried out by researchers from Oregon Health and Science University and the Salk Institute for Biological Studies in the US, the Institute for Basic Science and Seoul University in Korea, and BGI-Shenzen and BGI-Quingdao in China. It was funded by Oregon Health and Science University, the Institute for Basic Science, the G. Harold and Leila Y. Mathers Charitable Foundation, the Moxie Foundation and the Leona M. and Harry B. Helmsley Charitable Trust and the Shenzhen Municipal Government of China. The study was published in thepeer-reviewed journal Nature.

The Guardian carried a clear and accurate report of the study. While thereports fromITV News, Sky News and The Independent were mostly accurate,they over-stated the current stage of research, with Sky News and ITV News saying it could eradicate "thousands of inherited conditions" and the Independent claiming it "opens the possibility for inherited diseases to be wiped out entirely." While this may be possible, we don't know whether other inherited diseases might be as easily targeted as this gene mutation.

Finally, the Daily Mail rolls out the arguably tired clich of the technique leading to "designer babies", which seems irrelevant at this point. The CRISPR-cas9 technique is only in its infancy and (ethics aside) it's simply not possible to use genetic editing to select desirable characteristics most of which are not the result of one single, identifiable gene. No reputable scientist would attempt such a procedure.

This was a series ofexperiments carried out in laboratories, to test the effects of the CRISPR-Cas9 technique on human cells and embryos.

This type of scientific research helps us understand more about genes and how they can be changed by technology. It doesn't tell us what the effects would be if this was used as a treatment.

Researchers carried out a series of experiments on human cells, using the CRISPR-cas9 technique first on modified skin cells, then on very early embryos, and then on eggs at the point of fertilisation by sperm. They used genetic sequencing and analysis to assess the effects of these different experiments on cells and how they developed, up to five days.

They looked specifically to see what proportion of cells carrying faulty mutations could be repaired, whether the process caused other unwanted mutations, and whether the process repaired all, or just some of, thecells in an embryo.

They used skin cells (which were modified into stem cells) and sperm from one man, who carried the MYBPC3 mutation in his genome, and donor eggs from women without the genetic mutation. This is the mutation known to cause hypertrophic cardiomyopathy.

Normally in such cases, roughly half the embryos would have the mutation and half would not, as there's a 50-50 chance of the embryo inheriting the male or female version of the gene.

The CRISPR-cas9 technique can be used to select and delete specific genes from a strand of DNA. When this happens, usually the cut ends of the strand join together, but this causes problems so can't be used in the treatment of humans. The scientists created a genetic template of the healthy version of the gene, which they introduced at the same time as using CRISPR-cas9 to cut the mutated gene. They hoped the DNA would repair itself with a healthy version of the gene.

One important problem with changing genetic material is the development of "mosaic" embryos, where some of the cells have corrected genetic material and others have the original faulty gene. If this happened, doctors would not be able to tell whether or not an embryo was healthy.

The scientists needed to test all the cells in the embryos produced in the experiment, to see whether all cells had the corrected gene or whether the technique had resulted in a mixture.

They also did whole genome sequencing on some embryos, to test for unrelated genetic changes that might have been introduced accidentally during the process.

All embryos in the study were destroyed, in line with legislation about genetic research on embryos.

Researchers found that the technique worked on some of the stem cells and embryos, but worked best when used at the point of fertilisation of the egg. There were important differences between the way the repair worked on the stem cells and the egg.

The researchers found no evidence of mutations induced by the technique, when they examined the cellsin a variety of ways. However, they did find some evidence of gene deletions caused by DNA strands splicing (joining) themselves together without repairing the faulty gene.

The researchers say they have demonstrated how human embryos "employ a different DNA damage repair system" to adult stem cells, which can be used to repair breaks in DNA made using the CRISPR-cas9 gene-editing technique.

They say that "targeted gene correction" could "potentially rescue a substantial portion of mutant human embryos", and increase the numbers available for transfer for couples using pre-implantation diagnosis during IVF treatment.

However, they caution that "despite remarkable targeting efficiency", CRISPR-cas9-treated embryos would not currently be suitable for transfer. "Genome editing approaches must be further optimised before clinical application" can be considered, they say.

Currently, genetically-inherited conditions like hypertrophic cardiomyopathy cannot be cured, only managed to reduce the risk of sudden cardiac death. For couples where one partner carries the mutated gene, the only option to avoid passing it onto their children is pre-implantation genetic diagnosis. This involves using IVF to create embryos, then testing a cell of the embryo to see whether it carries the healthy or mutated version of the gene. Embryos with healthy versions of the gene are then selected for implantation in the womb.

Problems arise if too few or none of the embryos have the correct version of the gene. The researchers suggest their technique could be used to increase the numbers of suitable embryos.

However, the research is still at an early stage and has not yet been shown to be safe or effective enough to be considered as a treatment.

The other major factor is ethics and the law. Some people worry that gene editing could lead to "designer babies," where couples use the tool to select attributes like hair colour, or even intelligence. At present, gene editing could not do this. Most of our characteristics, especially something as complex as intelligence, are not the result of one single, identifiable gene, so could not be selected in this way. And it's likely that, even if gene editing treatments became legally available, they would be restricted to medical conditions.

Designer babies aside, society needs to consider what is acceptable in terms of editing human genetic material in embryos. Some people think that this type of technique is "playing God" or is ethically unacceptable because it involves discarding embryos that carry faulty genes. Others think that it's rational to use the scientific techniques we have developed to eliminate causes of suffering, such as inherited diseases.

This research shows that the questions of how we want to legislate for this type of technique are becoming pressing. While the technology is not there yet, it is advancing quickly. This research shows just how close we are getting to making genetic editing of human embryos a reality.

Excerpt from:
Gene editing used to repair diseased genes in embryos - NHS Choices

Redskins TE Jordan Reed’s toe injury flared up after a stem-cell treatment – Richmond.com

Speaking for the first time at training camp, Washington Redskins tight end Jordan Reed said Thursday afternoon his toe injury has been present since the end of the 2016 season.

Reed said the injury was nagging at him all last year and into the offseason. He said it was getting better, and he participated in the team's summer minicamp.

However, after the summer sessions, he got a stem-cell treatment on the toe.

"That kind of flared it up a bit on me," he said. "Now I'm just letting it calm down before I get out there."

Reed hasn't yet participated in training camp. He visited a specialist in Charlotte earlier this week, who recommended rest for Reed - that the tight end should let the toe fully heal before returning to the field.

Reed said in trying to play through the injury, he was potentially setting himself up for more damage.

"Because I want to keep pain from my toe, I'm rolling my ankle," he said.

Reed added: "I've just gotta take my time, let it heal and strengthen up, then get back out there."

mphillips@timesdispatch.com (804) 649-6546

Read more from the original source:
Redskins TE Jordan Reed's toe injury flared up after a stem-cell treatment - Richmond.com

Thunder journal: Focus turns to Alex Abrines’ health entering EuroBasket – NewsOK.com

Oklahoma City's Alex Abrines tires to defend a shot by Houston's James Harden during the NBA playoffs in April. Abrines is getting ready to play in a tournament in Europe. [PHOTO BY SARAH PHIPPS, THE OKLAHOMAN]

When Thunder players gathered last week on the West Coast for workouts, Alex Abrines was noticeably missing.

Abrines did not attend the Russell Westbrook-coordinated workouts in Santa Monica, California. It was always Abrines' plan to start his summer attending friends' weddings and traveling home to Spain before preparing for FIBA EuroBasket 2017. Since Friday, Abrines has been in the Spanish National Team training camp for EuroBasket, the 24-team European tournament which starts Aug. 31.

Spain, the reigning European champion, will play in seven exhibition games before its Eurobasket group-play opener against Serbia and Montenegro on Sept. 1 in Romania. Its first exhibition is Aug. 8 against Belgium in Tenerife, Spain.

What will be critical to watch is the health of Abrines following platelet rich plasma injections in his right knee in May. Abrines missed three games toward the end of the regular season with a left knee sprain, and has a history of knee soreness. He missed a game for Spain in last summer's Olympics with left knee discomfort and battled a bout of right knee tendonitis when playing for Barcelona in 2013.

Abrines told The Oklahoman in June that with extended rest he hopes he won't have to repeat the treatment for years.

It'd been four or five years since the last one, Abrines said in June. This year, we did the right thing, stopping for two weeks, then rehabbing a little bit, starting slowly. I think it's going to get better, and we don't have repeat it for the next three years at least (knocks on table).

Abrines remained relatively healthy in his first NBA season, playing in 68 of a possible 82 games while leading the Thunder in 3-point percentage (38.1 percent).

Collison likes the George gamble

While the trade of Jimmy Butler from Chicago to Minnesota or the potential of Kyrie Irving getting traded out of Cleveland can compete, the move for Paul George made by the Thunder is the biggest trade of the offseason.

It's also the biggest what if? of the summer. George can become a free agent in 2018, while players such as Butler and Irving each have two years left on their contracts. George's affinity for his native Los Angeles is well-documented, as is the Lakers having nearly $40 million in salary coming off its payroll next summer.

Just by keeping the current roster together, the Thunder is assured a Western Conference contender this season, but beyond?

Thunder veteran Nick Collison said no matter the risk factor of the George trade, he likes the move. And so does the rest of the Thunder.

You love that the front office is trying to do that to win, Collison said. As players, we're just thinking about the season, and I understand there's other decisions that have to be made for the future of the franchise, but it's the move they decided to make. I think as players, we're excited about it.

Sam's job is to put the players here. Billy's job is to coach the team. The players' job is to be ready to play. The direction that they want to go is up to them, but as a player I think you love it when they add a guy like that if you feel like it's gonna make the team better, which I do.

Read the original here:
Thunder journal: Focus turns to Alex Abrines' health entering EuroBasket - NewsOK.com

Healing Osteoarthritis with Stem Cells – Anti Aging News

1079 0 Posted on Aug 03, 2017, 7 a.m.

Stem cell therapies provide an alternative to pain relievers and total joint replacement for those suffering from osteoarthritis.

Osteoarthritis plagues millions of older adults throughout the world. It is the most common type of degenerative joint disease. Commonly referred to as OA, osteoarthritis is an inevitability for many people. It occurs as the rubber-like cartilage that protects the ends of human bones gradually breaks down. It eventually leads to a situation where bones rub against one another as little, if any, cartilage remains. OA can occur in any of the body's joints. However, it is more common in the hips, knees, spine and hands.

OA sounds like a particularly gruesome condition with painful bone-on-bone contact yet hope is available. Patients currently use physical therapy, pain relievers, cortisone injections and even surgery. Scientists have recently pinpointed stem cells as a possible catalyst for OA healing.

How the Human Body Might be Able to Heal Itself

Emory Orthopaedics and Spine Center physicians made waves five years ago when they launched regenerative stem cell therapy. This is a form of treatment for OA as well as related joint maladies. It makes use of the patient's stem cells to remedy damaged tissues, minimize pain and hasten the healing process. Stem cells are taken from the patient's body with a needle. These stem cells are derived from abdominal fat and/or the hip's bone marrow. They are then placed in a centrifuge and spun in a rapid manner to generate a concentrate. This process isolates the stem cells. These cells are injected right back into the patient's compromised joint minutes later. This reapplication of stem cells catalyzes the healing process.

The use of stem cells takes about an hour and a half. The best part is it involves minimal comfort and produces few side effects for the vast majority of patients. The stem cells are taken from the patient himself in order to decrease the odds of rejection. This method of treatment has proven quite effective, helping patients enjoy a substantial improvement in joint health in as little as one month.

Stem Cells: The Darling of Regenerative Medicine

The medical community is quickly determining stem cells enhance the healing process better than other treatments. The predecessor was platelet-rich plasma for the treatment of OA and joint damage. This method debuted nearly a decade ago. Stem cell therapy launched in 2012 and has proven incredibly effective. Stem cells are highly specialized cells that can replicate themselves and potentially differentiate into different cell types for varying functions within the body.

Though there are numerous different stem cell types, those that help promote ligament, tendon and cartilage healing are referred to as mesenchymal stem cells. The human body has a substantial amount of these cells available to repair damaged tissues. Though there is minimal evidence that adding a concentration of such cells can replace joint cartilage that has been lost, they serve as important signaling cells that promote the transmission of proteins like cytokines. These are molecular harbingers that mitigate cartilage degeneration and control pain.

Advancements in stem cells might eventually make it theoptimal means of repair for cartilage cells. Such cells aredamaged due to everyday wear and tear, sports participation, obesity, andgenetics. As of now, stem cells have proven quite effective in reducing the stiffness and pain tied to OA. It is an excellent alternative to total joint replacement surgery and pain relievers.

The FDA's Take on Stem Cells

Certain medical professionals consider stem cells to be an experimental treatment. The FDA is now attempting to determine how the number of stem cell therapies should be regulated. Unfortunately, many types of insurance do not cover stem cell treatments. Stay tuned for more developments.

See the rest here:
Healing Osteoarthritis with Stem Cells - Anti Aging News

CRISPR Corrects Disease Mutation in Human Embryos – Genetic Engineering & Biotechnology News (blog)

In an unexpected twist, the investigators discovered that once the paternal gene was excised, the genetic material originating from the mother (i.e., the homologous wild-type maternal gene) was more easily substituted than the synthetic DNA the scientists attempted to introduce.

To reduce mosaicism, which is characterized by a population of cells that originate from one egg but are genetically distinct, researchers injected sperm cells and CRISPR components directly into oocytes early in their cell-cycle phase, only 18 hours post-fertilization. The study authors assumed this would be the best time for genome editing to occur, as the sperm at that time only has a single mutant copy. In addition, injecting genetic material early, before DNA replication occurred, meant that the CRISPR components stayed in the cytoplasm longer. As a result of prolonged cytoplasm residency, the CRISPR components degraded quickly, before further replication of mutant alleles could occur.

Mosaicism, noted the authors, could have major negative effects and could restrict the clinical applications of the gene-editing technique in embryos, a fact that the authors identified as a limitation. In addition, the uncertainty surrounding the ability to reproduce the studys findings was also a limitation, the authors acknowledged.

Employing CRISPR in embryos, rather than in stem cells, yielded better results: The overall targeting efficiency in human embryos was found to be 72.2% (13/18), which was higher than the rate in induced pluripotent stem cells (iPSCs) exposed to the same construct (27.9%, or 17/61). The higher targeting efficiency suggests that human embryos employ different DNA repair mechanisms than do somatic or pluripotent cells, probably reflecting evolutionary requirements for stringent control over genome fidelity in the germline," the authors wrote in the paper.

Because off-target cutting is also a concern withCRISPR/Cas9, researchers evaluated all of the potential off-target sites via a whole-genome sequencing analysis. They determined that their technique did not produce any detectable off-target mutations in the blastomeres.

And, because Cas9 was used in purified protein form, and was not contained in a plasmid, off-site targeting was further reduced, investigators concluded.

Excerpt from:
CRISPR Corrects Disease Mutation in Human Embryos - Genetic Engineering & Biotechnology News (blog)

World’s 1st trial of drug developed from iPS cells to begin – Japan … – Japan Today

Japanese researchers are set to begin the world's first clinical trial of a drug developed from iPS stem cells to treat a rare bone disease, Kyoto University said Tuesday.

A team led by Junya Toguchida, professor at the university, used so-called induced pluripotent stem cells to develop a potential drug for fibrodysplasia ossificans progressiva, or FOP, a rare disorder in which muscle tissue is gradually replaced by bone, inhibiting body movement.

The researchers created iPS cells from FOP patients and replicated the symptom outside their bodies. After adding components to the cells with features of the disease, they found an immune-suppressive agent called Rapamycin is effective for preventing abnormal bone formation.

The drug's safety and effectiveness need to be tested in a clinical trial, which could begin as early as September, on 20 patients aged 6 or older. A review committee at Kyoto University Hospital has already approved the trial.

The team has confirmed the effectiveness of Rapamycin in experiments with mice. Researchers gave the agent to mice after transplanting FOP patients' iPS stem cells into them and found out that the drug inhibited abnormal born formation.

"Rapamycin is a drug already used (for treatment of other diseases) so I expect patients will welcome" its use in the clinical trial, Toguchida said at a press conference.

Shinya Yamanaka, professor at Kyoto University and a 2012 Nobel Prize winner in medicine for discovering iPS cells, said, "I hope the clinical trial will spur active research for drug development and eventually lead to the discoveries of new treatment for various rare diseases."

The disease is caused by a mutation of a gene called ACVR1. Bones are formed in muscles, tendons and ligaments, hindering the movements of joints. Patients may experience difficulty in breathing if their respiratory muscles are affected.

iPS cells can grow into any type of human body tissue. They are expected to be utilized for drug development as well as regenerative medicine.

Follow this link:
World's 1st trial of drug developed from iPS cells to begin - Japan ... - Japan Today

Honor for pioneering equine stem cell researcher – Horsetalk

An equine cartilage disk, of about 4mm in diameter, is being used in trials in Canada, thanks to stem cell researcher Dr Thomas Koch.

An equine stem cell researcher is among theinaugural recipients of new University of Guelph internal awards recognizing research excellence and innovation.

Dr Thomas Koch, from Ontario Veterinary Colleges Department of Biomedical Sciences, has received a Research Excellence Award.

The awards recognize both researchers who are embarking on stellar careers and those whose research successes already set them apart from their colleagues in their disciplines globally, said University of Guelphvice-president (research) Malcolm Campbell.

Koch, who was recently recognized with a 2016 Early Researcher Award from the Ontario Ministry of Research and Innovation, focuses his research on stem cell biology, tissue engineering-based therapies and regenerative medicine. In particular he is studying the potential of stem cells to repair damage to joints and cartilage. His work on equine stem cells for cartilage repair includes finding better ways to treat horses, as well as using the horse as a model for testing new therapies for humans. Koch is also a founding member and current vice-chair of the North American Veterinary Regenerative Medicine Association.

In 2012, Koch isolated mesenchymal stromal cells (MSCs) for potential cartilage repair using a simple, non-invasive procedure.

He was recognised along with DrShayan Sharif, a professor of poultry immunology at the OVCs Department of Pathobiology, who received a Research Leadership Chair.

Drs Sharif and Koch are among our best: they were nominated by their peers, not only because of their outstanding scholarly accomplishments, but also because they are exemplary citizens of the University of Guelph, said OVC Dean Jeff Wichtel.

The Chair and the Award are well-deserved acknowledgements of their continued commitment to research excellence in their respective disciplines, and highlight once again OVCs strengths in translational medicine, food animal production, food safety and security.

Created by the U of Gs Office of Research and the Office of the Provost, the awards will be made annually.

Research Excellence awards are a one-time, $5000 award. Early career faculty who are one to two years post-tenure are eligible. Research Leadership Chairs are for well-established faculty who have demonstrated research excellence. The $15,000 awards are for three years, with a possible extension to five years.

Award winners will present their work to U of G and the wider Guelph community through special research events. Each of U of Gs seven colleges will be eligible for one Research Excellence Award recipient and up to two Research Leadership Chairs. Recipients are nominated and selected by their respective colleges. Awards are based on scholarly output, research-related knowledge mobilization, research-derived innovation and training of highly qualified personnel.

Visit link:
Honor for pioneering equine stem cell researcher - Horsetalk

Skin graft gene therapy could treat obesity and diabetes – ResearchGate (blog)

In a new study, researchers at the University of Chicago have provided proof of concept for a new form of gene therapy that is administered via a skin transplant. In the study, they treated type-2 diabetes and obesity in mice by inserting the gene for a glucagon-like peptide 1 (GLP1) that stimulates the pancreas to secrete insulin. The extra insulin can prevent diabetes complications by removing excessive glucose from the bloodstream. It can also delay gastric emptying and reduce appetite.

We spoke to one of the studys authors, Xiaoyang Wu, about the work.

ResearchGate: What motivated this study?

Xiaoyang Wu: We have been working on skin somatic stem cells for a long time. As one of the most studied adult stem cell systems, skin stem cells have several unique advantages as the novel vehicle for somatic gene therapy. For one, the system is well established. Human skin transplantation using a CEA device developed from skin stem cells has been used clinically for decades for burn wound treatment, and is proven to be safe and effective.

RG: Can you tell us what you achieved?

Xiaoyang Wu: We established a novel mouse to mouse skin transplantation system to test skin gene therapy. In the proof-of-concept study, we showed that we can achieve the systematic release of GLP1 at therapeutic concentration by engineered skin grafts.

RG: How does this work to treat obesity and diabetes?

Xiaoyang Wu: When engineered to express therapeutic hormones, such as GLP1, the skin grafts can be used to suppress body weight gain, and development of type 2 diabetes.

RG: What were some of the challenges in development? How did you overcome them?

Xiaoyang Wu: The mouse skin transplantation system has not been well established before. We circumvented the technical issues by building a novel skin organoid culture system in vitro.

RG: Are there alternate methods to delivery this type of therapy, and if so why is skin better?

Xiaoyang Wu: The GLP1 receptor agonist can be applied with an injection, but the half-life will be short. Skin based gene delivery provides a long term and safe way for drug delivery in vivo.

RG: Do think this would have a similar effect in humans?

Xiaoyang Wu: Our proof-of-concept work demonstrated its possible to use engineered skin grafts to treat many non-skin diseases. Clinical translation of our findings will be relatively easy, as skin transplantation in human patients has been well established and clinically used for treatment of burn wounds for many years.

RG: Whats next for your research?

Xiaoyang Wu: Before clinical translation, we will further characterize our mouse model of skin therapy, looking at potential immune reaction, stability of skin grafts, and duration of the therapeutic effects. We are also interested in using our mouse model to test other potential applications of skin gene therapy, such as human genetic diseases, including hemophilia and urea cycle disorders.

Featured image courtesy ofMehmet Pinarci.

The rest is here:
Skin graft gene therapy could treat obesity and diabetes - ResearchGate (blog)

Kite Seeks EU Approval for CAR T-Cell Therapy in 3 Lymphoma Subtypes – Lymphoma News Today

Kite Pharma submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) requesting the approval of its CAR T-cell therapy, axicabtagene ciloleucel, as treatment for patients with certain lymphomas.

The include relapsed or refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL), and primary mediastinal B-cell lymphoma (PMBCL), who cannot receive autologous stem cell transplants.

This is the first application for a CAR T-cell therapy ever submitted to the EMA.

The MAA submission of axicabtagene ciloleucel marks an important global milestone in the development of engineered T-cell therapy, Arie Belldegrun, MD, president and CEO of Kite, said in a press release.

He said the company is excited to be working with the EMAs Committee for Medicinal Products for Human Use (CHMP) and Committee for Advanced Therapies (CAT) to help bring this potentially transformative therapy to patients in the EU.

Axicabtagene ciloleucel, formerlyknown as KTE-C19, is a CAR (chimeric antigen receptor) T-cell therapy. The treatment consist of collecting the patients own T-cells and modifying them to express aCAR protein that recognizes the surface protein CD19, a molecule that is widelyexpressed by B-cell lymphomas and leukemias.

Kites application includes primary data from the ZUMA-1 trial (NCT02348216), a Phase 1/2 trial testing axicabtagene ciloleucel in treatment-resistant or relapsed aggressive non-Hodgkins lymphomapatients. The trial included 101 patients withDLBCL, PMBCL, or TFL, most with advanced-stage disease.

Data presented late June at the 22nd Congress of theEuropean Hematology Association(EHA),showed that 82 percent of patients responded to treatment after a single infusion of axicabtagene ciloleucel. This positive response was sustained in 44 percent of patients after amedian follow-up time of 8.7 months. At that time, 39 percent of patients exhibiteda complete response.

The most common severe treatment-related adverse eventsreported inZUMA-1 included cytokine release syndrome and neurologic events, which were generally reversible aftersuitable management.

Axicabtagene ciloleucelhas been designated a breakthrough therapy by the U.S. Food and Drug Administration for the treatment of DLBCL, TFL, and PMBCL, and received priority medicines (PRIME) regulatory support in the European Union. These designationsare meant to support a drugsdevelopment and accelerate its regulatory review.

The FDA is reviewingKites biologics license application (BLA) submitted for axicabtagene ciloleucel for the treatment of refractory aggressive non-Hodgkins lymphoma. A final decision is expected by Nov. 29.

Read more:
Kite Seeks EU Approval for CAR T-Cell Therapy in 3 Lymphoma Subtypes - Lymphoma News Today